Developer docs
API playgroundTry for free, no card

Search company profiles

Hikma Ventures

Full company profile

uuid0000b2u

Namestring
Hikma Ventures
Legal namestring
Hikma Ventures Ltd
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Hikma Ventures is the strategic corporate venture capital arm of Hikma Pharmaceuticals PLC, established in 2015 and headquartered in London. The firm operates an evergreen fund of $100 million to invest in innovative digital health and life sciences companies, deploying capital stage-agnostically with a preference for Series A and beyond and ticket sizes of up to $5 million per company per round. Its portfolio spans roughly 18 active companies and over 20 investments to date across drug delivery, digital therapeutics, clinical trial innovation, respiratory care, CNS, oncology, autoimmune and chronic diseases (including type II diabetes and hypertension), and overdose/abuse prevention.

The fund's core offering is strategic capital plus operational leverage from Hikma Pharmaceuticals, a FTSE 100-listed pharma group operating 58 subsidiaries across 11 countries with 29 manufacturing plants and 8 R&D centres in MENA, Europe, and North America. Portfolio companies gain access to Hikma's regulatory pathways, manufacturing infrastructure, and distribution network, while Hikma gains exposure to disruptive digital health innovations. The team is lean (Managing Director Lana Ghanem, Principal Salma Al-Zu'bi, Analyst Haya Khoury) and is augmented by an advisory board of senior pharma operators and healthcare investment bankers.

Hikma Ventures does not charge external management fees and is wholly funded by Hikma Pharmaceuticals PLC. Returns are realized exclusively through portfolio exits; six documented exits include Lemonaid Health (acquired by 23andMe), Nebula Genomics (ProPhase Labs), Pillo Health (Stanley Black & Decker), Propeller Health (ResMed), Tact.ai (Aktana), and Winterlight Labs (Cambridge Cognition). The fund does not disclose standalone revenue or financial statements, and its investment cadence of approximately two deals per year reflects a measured, thesis-driven deployment strategy rather than scale-driven fund growth.

Short descriptiontext

Hikma Ventures is the London-based corporate venture arm of Hikma Pharmaceuticals PLC, deploying a $100 million evergreen fund into digital health and life sciences startups worldwide with up to $5 million per round.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, digital health investments, life sciences funding, corporate venture capital, pharmaceutical strategic investments
Industry1 code
PRIMARYFSANAHAN
Corporate Strategic Real Assets & Infrastructure Venture Investing
NAICS code1 code
  • All Other Financial Investment Activities52399
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Returns
TypeLicensing Royalties
Description

Hikma Ventures generates returns through equity investments in portfolio companies. The evergreen fund structure allows for long-term investment perspective. Returns are realized through exits (acquisitions, IPOs) and provide strategic value to parent company Hikma Pharmaceuticals by broadening offerings and tapping into digital health and life sciences opportunities.

hikmaventures.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Hikma Ventures is the strategic corporate venture capital arm of Hikma Pharmaceuticals PLC, established in 2015 with a $100 million evergreen fund. The firm makes equity investments in innovative digital health and life sciences companies worldwide, focusing on drug delivery, digital therapeutics, clinical trial innovation, respiratory, CNS, oncology, autoimmune and chronic diseases. Investments are stage-agnostic with a preference for Series A and beyond, with average ticket sizes up to $5 million per company per round.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Hikma Ventures is the strategic venture capital arm of Hikma Pharmaceuticals, established in 2015 with a $100 million evergreen fund. The firm invests in innovative digital health and life sciences companies worldwide, with a focus on drug delivery, digital therapeutics, clinical trial innovation, respiratory, CNS, oncology, autoimmune and chronic diseases. The portfolio consists of 20+ investments, including both active portfolio companies and acquired entities. Investment strategy is stage-agnostic with preference for Series A and beyond, with average ticket sizes of up to $5 million per company per round. The firm leverages Hikma's global pharmaceutical expertise and presence to drive portfolio company success.

Product and service1 record
1Hikma Ventures Portfolio
CategoryInvestment Services
Description

Strategic venture capital investments in innovative digital health and life sciences companies worldwide, covering drug delivery, digital therapeutics, clinical trial innovation, respiratory, CNS, oncology, autoimmune and chronic diseases. Portfolio includes approximately 18 active companies plus former portfolio companies acquired by larger firms.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Corporate venture capital arm of Novartis focused on innovative therapeutics and digital health investments. Most direct comparable as a pharma CVC with similar strategic mandate and evergreen-style long-term investment horizon.

TypeDirect peer
Description

Corporate venture capital arm of Sanofi investing in digital health, biotech, and life sciences companies. Highly comparable as another pharma CVC with similar stage-agnostic approach and portfolio construction strategy.

TypeDirect peer
Description

Corporate venture arm of Roche focused on early-stage diagnostics, digital health, and therapeutic investments. Comparable as a European-headquartered pharma CVC with similar evergreen structure and strategic capital deployment.

TypeDirect peer
Description

Corporate venture capital arm of Pfizer investing in therapeutic, diagnostic, and digital health startups. Comparable in mandate and stage preferences, with similar focus on healthcare innovation adjacencies to core pharma operations.

5Bayer Leaps by Bayer
TypeDirect peer
Description

Bayer's corporate venture arm focused on breakthrough health and agriculture technologies. Comparable as a strategic pharma CVC with similar cross-portfolio support model for portfolio companies.

TypeDirect peer
Description

Corporate venture arm of Amgen investing across therapeutic areas and digital health. Comparable as a US-headquartered pharma CVC with similar evergreen capital structure and strategic investment focus.

TypeDirect peer
Description

Merck's corporate venture capital fund focused on digital health, health IT, and life sciences. Comparable as a pharma CVC with evergreen fund structure and similar emphasis on strategic distribution and partnership for portfolio companies.

TypeDirect peer
Description

Corporate venture arm of Boehringer Ingelheim focused on early-stage biotech, digital health, and innovative therapeutics. Comparable as a European pharma CVC with similar evergreen structure and mission-driven investment thesis.

TypeDirect peer
Description

GSK's strategic venture activities target innovative biotech and digital health opportunities. Comparable as a global pharma corporate investor with similar focus on strategic health technology adjacencies.

TypeBroad incumbent
Description

Venture capital arm of Optum (UnitedHealth Group) focused on healthcare data, digital health, and care delivery innovation. Comparable as a healthcare strategic CVC investing in overlapping categories (digital therapeutics, clinical trials) but with a larger, US-focused mandate and payor-provider ecosystem advantage.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment28 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hikma Ventures

Venture Capitalhikmaventures.com

Hikma Ventures is the London-based corporate venture arm of Hikma Pharmaceuticals PLC, deploying a $100 million evergreen fund into digital health and life sciences startups worldwide with up to $5 million per round.

What Hikma Ventures does

Hikma Ventures is the strategic corporate venture capital arm of Hikma Pharmaceuticals PLC, established in 2015 and headquartered in London. The firm operates an evergreen fund of $100 million to invest in innovative digital health and life sciences companies, deploying capital stage-agnostically with a preference for Series A and beyond and ticket sizes of up to $5 million per company per round. Its portfolio spans roughly 18 active companies and over 20 investments to date across drug delivery, digital therapeutics, clinical trial innovation, respiratory care, CNS, oncology, autoimmune and chronic diseases (including type II diabetes and hypertension), and overdose/abuse prevention.

The fund's core offering is strategic capital plus operational leverage from Hikma Pharmaceuticals, a FTSE 100-listed pharma group operating 58 subsidiaries across 11 countries with 29 manufacturing plants and 8 R&D centres in MENA, Europe, and North America. Portfolio companies gain access to Hikma's regulatory pathways, manufacturing infrastructure, and distribution network, while Hikma gains exposure to disruptive digital health innovations. The team is lean (Managing Director Lana Ghanem, Principal Salma Al-Zu'bi, Analyst Haya Khoury) and is augmented by an advisory board of senior pharma operators and healthcare investment bankers.

Hikma Ventures does not charge external management fees and is wholly funded by Hikma Pharmaceuticals PLC. Returns are realized exclusively through portfolio exits; six documented exits include Lemonaid Health (acquired by 23andMe), Nebula Genomics (ProPhase Labs), Pillo Health (Stanley Black & Decker), Propeller Health (ResMed), Tact.ai (Aktana), and Winterlight Labs (Cambridge Cognition). The fund does not disclose standalone revenue or financial statements, and its investment cadence of approximately two deals per year reflects a measured, thesis-driven deployment strategy rather than scale-driven fund growth.

Hikma Ventures firmographics

Firmographics
Name
Hikma Ventures
Legal name
Hikma Ventures Ltd
Website
https://hikmaventures.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Hikma Ventures is the London-based corporate venture arm of Hikma Pharmaceuticals PLC, deploying a $100 million evergreen fund into digital health and life sciences startups worldwide with up to $5 million per round.
Ownership category
akta.pro rank

Hikma Ventures industry classification

Industry
Product category
Venture Capital
NAICS
All Other Financial Investment Activities (52399)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAHAN
Corporate Strategic Real Assets & Infrastructure Venture Investing

Keywords

  • Venture capital investing
  • Digital health investments
  • Life sciences funding
  • Corporate venture capital
  • Pharmaceutical strategic investments

Where Hikma Ventures is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Hikma Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations

Revenue model

  1. Investment Returns: Hikma Ventures generates returns through equity investments in portfolio companies. The evergreen fund structure allows for long-term investment perspective. Returns are realized through exits (acquisitions, IPOs) and provide strategic value to parent company Hikma Pharmaceuticals by broadening offerings and tapping into digital health and life sciences opportunities.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Hikma Ventures product offering

Product offering

Core offering

Hikma Ventures is the strategic corporate venture capital arm of Hikma Pharmaceuticals PLC, established in 2015 with a $100 million evergreen fund. The firm makes equity investments in innovative digital health and life sciences companies worldwide, focusing on drug delivery, digital therapeutics, clinical trial innovation, respiratory, CNS, oncology, autoimmune and chronic diseases. Investments are stage-agnostic with a preference for Series A and beyond, with average ticket sizes up to $5 million per company per round.

Product overview

Hikma Ventures is the strategic venture capital arm of Hikma Pharmaceuticals, established in 2015 with a $100 million evergreen fund. The firm invests in innovative digital health and life sciences companies worldwide, with a focus on drug delivery, digital therapeutics, clinical trial innovation, respiratory, CNS, oncology, autoimmune and chronic diseases. The portfolio consists of 20+ investments, including both active portfolio companies and acquired entities. Investment strategy is stage-agnostic with preference for Series A and beyond, with average ticket sizes of up to $5 million per company per round. The firm leverages Hikma's global pharmaceutical expertise and presence to drive portfolio company success.

Differentiator

Problem solved

Functional benefit

Products and services

  • Hikma Ventures Portfolio Strategic venture capital investments in innovative digital health and life sciences companies worldwide, covering drug delivery, digital therapeutics, clinical trial innovation, respiratory, CNS, oncology, autoimmune and chronic diseases. Portfolio includes approximately 18 active companies plus former portfolio companies acquired by larger firms.

Companies that use Hikma Ventures

Customer profile

Segments1 record

Ideal customer profiles1 record

Hikma Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Hikma Ventures partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Hikma Ventures competitors and assessment

Company assessment

Direct peers

  • Novartis Venture Fund: Corporate venture capital arm of Novartis focused on innovative therapeutics and digital health investments. Most direct comparable as a pharma CVC with similar strategic mandate and evergreen-style long-term investment horizon.
  • Sanofi Ventures: Corporate venture capital arm of Sanofi investing in digital health, biotech, and life sciences companies. Highly comparable as another pharma CVC with similar stage-agnostic approach and portfolio construction strategy.
  • Roche Venture Fund: Corporate venture arm of Roche focused on early-stage diagnostics, digital health, and therapeutic investments. Comparable as a European-headquartered pharma CVC with similar evergreen structure and strategic capital deployment.
  • Pfizer Ventures: Corporate venture capital arm of Pfizer investing in therapeutic, diagnostic, and digital health startups. Comparable in mandate and stage preferences, with similar focus on healthcare innovation adjacencies to core pharma operations.
  • Bayer Leaps by Bayer: Bayer's corporate venture arm focused on breakthrough health and agriculture technologies. Comparable as a strategic pharma CVC with similar cross-portfolio support model for portfolio companies.
  • Amgen Ventures: Corporate venture arm of Amgen investing across therapeutic areas and digital health. Comparable as a US-headquartered pharma CVC with similar evergreen capital structure and strategic investment focus.
  • Merck Global Health Innovation Fund: Merck's corporate venture capital fund focused on digital health, health IT, and life sciences. Comparable as a pharma CVC with evergreen fund structure and similar emphasis on strategic distribution and partnership for portfolio companies.
  • Boehringer Ingelheim Venture Fund: Corporate venture arm of Boehringer Ingelheim focused on early-stage biotech, digital health, and innovative therapeutics. Comparable as a European pharma CVC with similar evergreen structure and mission-driven investment thesis.
  • GSK (CVC activities via Action Fund and others): GSK's strategic venture activities target innovative biotech and digital health opportunities. Comparable as a global pharma corporate investor with similar focus on strategic health technology adjacencies.

Broad incumbents

  • Optum Ventures: Venture capital arm of Optum (UnitedHealth Group) focused on healthcare data, digital health, and care delivery innovation. Comparable as a healthcare strategic CVC investing in overlapping categories (digital therapeutics, clinical trials) but with a larger, US-focused mandate and payor-provider ecosystem advantage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Hikma Ventures social profiles

Digital presence

Hikma Ventures compliance and trust

Trust signal

Compliance3 records

Hikma Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hikma Ventures leadership team

Management profile

Number of profiles

Profiles12 records

Hikma Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hikma Ventures M&A and investment

M&A and investment

M&A

Investments28 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hikma Ventures

What does Hikma Ventures do?

Hikma Ventures is the strategic corporate venture capital arm of Hikma Pharmaceuticals PLC, established in 2015 with a $100 million evergreen fund. The firm makes equity investments in innovative digital health and life sciences companies worldwide, focusing on drug delivery, digital therapeutics, clinical trial innovation, respiratory, CNS, oncology, autoimmune and chronic diseases. Investments are stage-agnostic with a preference for Series A and beyond, with average ticket sizes up to $5 million per company per round.

Is Hikma Ventures a public or private company?

Hikma Ventures is a private company. It is classified as corporate owned and is currently operating.

When was Hikma Ventures founded?

Hikma Ventures was founded in 2015. It employs 11 to 50 people.

Where is Hikma Ventures based?

Hikma Ventures is headquartered in London, United Kingdom, in the Europe region.

How does Hikma Ventures make money?

One revenue line is on record: investment Returns.

Who are Hikma Ventures's main competitors?

Direct peers on record are Novartis Venture Fund, Sanofi Ventures, Roche Venture Fund, Pfizer Ventures, Bayer Leaps by Bayer, Amgen Ventures, Merck Global Health Innovation Fund, Boehringer Ingelheim Venture Fund and GSK (CVC activities via Action Fund and others). Optum Ventures is listed as a broad incumbent.

Does Hikma Ventures have an API?

No public API is recorded for Hikma Ventures.

What industry is Hikma Ventures in?

Hikma Ventures's product category is Venture Capital. Its primary akta.pro industry code is FSANAHAN, Corporate Strategic Real Assets & Infrastructure Venture Investing. Its NAICS code is 52399 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InsidermediaCompany behind prominent nutrition brand lines up expansion after securing Hikma Ventures backingRem3dy Health, behind the Nourished nutrition brand, secured Hikma Ventures investment to support global expansion. The company reported a 61% revenue rise to £10.2m and will launch 3D-printed supplements in seven MENA markets, starting in the UAE, Saudi Arabia, and Jordan in Q1 2027.Dealroom.coHikma Ventures backs 3D-printing nutrition firm Rem3dy in first wellness bet | Dealroom NewsHikma Ventures made a strategic investment in Rem3dy Health, a UK 3D-printing nutrition firm, and secured an exclusive commercial deal to bring its Nourished brand to the Middle East and North Africa, targeting Saudi Arabia and the UAE. The investment pairs with Hikma's existing distribution agreement for the region, marking Hikma Ventures' first wellness investment.FwdstartBioSapien wins Abu Dhabi regulatory approvals to begin Phase I cancer trials for its MediChip platformBioSapien received regulatory approvals from Abu Dhabi's Department of Health and Emirates Drug Establishment to begin Phase I clinical trials for its MediChip cancer drug-delivery platform. The trials will start in colorectal cancer, with potential extension to pancreatic and lung cancers. The company expects patient enrolment and trial initiation within weeks.Global VenturingHadi joins industrial group Angelini’s startup investment arm as senior principalHamzeh Abdul Hadi has joined Angelini Ventures, the VC arm of Italian industrial group Angelini Industries, as senior principal based in Dubai to focus on health tech investments. He previously served as investment director at Debiopharm Innovation Fund and spent nearly six years at Hikma Ventures, while also founding men's sexual health platform Al-Alpha Health. Angelini Ventures recently entered a deal with the European Investment Bank to deploy a €150m fund backing 10 European health tech startups, including investments in Laigo Bio, CoMind, and Adcytherix.AETOSWireActiv Surgical, a Hikma Ventures portfolio company, completes the first international procedure using ActivSight™ Intelligent Light at Abdali Hospital in JordanActiv Surgical completed its first international surgery using ActivSight at Abdali Hospital in Amman, Jordan. The procedure was a bariatric revision performed by Dr. Mohamad Rassoul Abu-Nuwar, with ActivSight's ActivPerfusion mode providing real-time tissue perfusion visualization. Hikma Ventures, the company's investor, highlighted the milestone as part of its commitment to advancing surgical technology in the MENA region.PR NewswireHikma Ventures invests in Octave Bioscience, a precision care platform for Multiple Sclerosis and other neurodegenerative diseasesHikma Pharmaceuticals announced that its venture capital arm, Hikma Ventures, has invested in Octave Bioscience, a developer of precision care platforms for neurodegenerative diseases. The investment supports Octave's commercialization efforts for its multiple sclerosis solution and expansion into other conditions like Parkinson's and Alzheimer's. This partnership aims to address unmet diagnostic needs and improve patient outcomes through digital health innovations.My Startup WorldHikma Ventures leads seed financing round for Egypt based O7 TherapyHikma Ventures, the venture capital arm of Hikma Pharmaceuticals, led a seed financing round for O7 Therapy, an online mental health platform serving Arabic speakers. This investment marks the largest announced seed round for a MENA-based mental health startup and includes participation from C-Ventures and Lotus Ventures.PR NewswireHikma Ventures Participates in USD 44 Million Financing Round for Altibbi to Expand the Platform's Reach across MENAHikma Pharmaceuticals announced on March 28, 2022 that its venture capital arm, Hikma Ventures, participated in Altibbi's Series B round, with the total amount not disclosed. Altibbi, a telehealth platform serving Arabic speakers, reported two million pages of medical content, 20 million monthly visitors and 3 million consultations annually. Proceeds will fund team growth, technology investment and new MENA products.HikmaHikma Ventures Participates in USD 44 Million Financing Round for Altibbi to Expand the Platform’s Reach across MENAHikma Pharmaceuticals PLC announced that its venture capital arm, Hikma Ventures, participated in a USD 44 million Series B financing round for the digital health platform Altibbi. The funds will be used to expand Altibbi's operations, talent, and technology across the Middle East and North Africa (MENA) region. This investment follows existing strategic partnerships between Hikma and Altibbi in Jordan, Egypt, and Lebanon.PR NewswireHikma Ventures leads Series B extension in Activ Surgical to support the global commercialization of its platformHikma Pharmaceuticals PLC announced that its venture capital arm, Hikma Ventures, led a $15 million USD extension of Activ Surgical's Series B financing round to support the commercialization of its ActivSight imaging module. This brings the total amount raised in the Series B round to $60 million USD and aims to enhance surgical decision-making through augmented reality and AI technologies. The investment will facilitate Activ Surgical's global launch of its product, enhancing surgical care and patient safety.